Prothena Corp (PRTA) Stock Price, Quote & News

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of tr...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 236 2500

Fax: 353 1 902 3510

Website: www.prothena.com

Address:

77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland

buyandsold Apr. 11 at 2:58 PM

$PRTA just announced investment to "further elucidate the potential of our preclinical programs and CYTOPE® technology." Setting our dollars alight. I may exit in disgust.

0 · Reply

Doozio Apr. 8 at 5:20 AM

$PRTA chop chop huckleberries let’s go rockin up da Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

buyandsold Mar. 25 at 8:07 PM

$PRTA they better be in buyback Xtreme mode at this discounr or Im gonna lose it

0 · Reply

Quantumup Mar. 25 at 2:15 PM

Morgan Stanley🏁 $IMMX Overweight; $20 $PRTA $AZN ABBV GSK JNJ - LEGN Citizens (A/O 3/9)🏁Market Outperform; $23 Here's what Morgan Stanley and Citizens said in their initiation reports: https://x.com/Quantumup1/status/2036808396326805561?s=20

0 · Reply

buyandsold Mar. 24 at 8:07 PM

$PRTA how this is not $12 i have no concept. Will they ever use the buyback. Restricted is a fantasy

0 · Reply

SuperGreenToday Mar. 24 at 1:52 AM

$PRTA Share Price: $8.81 Contract Selected: Sep 18, 2026 $10 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.24 – $1.51 Potential Upside: 62% ROI Time to Expiration: 178 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

buyandsold Mar. 23 at 1:50 PM

$PRTA truly an unloved stock. If management is not using all its buyback allocation at these sub $9 levels its criminal. They have literally nothing else to do than get this right. Increase my holding by 50% at market open. It is still only 2/3 of what I owned in the past, and is now 2nd biggest holding after $SRPT

0 · Reply

takingstock73 Mar. 23 at 12:49 PM

$PRTA nice reiterate today

1 · Reply

SKVT Mar. 17 at 5:56 AM

$RHHBY roche will make a big announcement in AD/PD 2026. Prasinezumab trial 3 will be a game changer in parkinson's disease. $PRTA

2 · Reply

SKVT Mar. 17 at 5:54 AM

$PRTA ROCHE will make a big announcement in ADPD2026. Prasinezumab will be a big thing!!

0 · Reply

Prothena Announces Leadership Team Updates

Mar 21, 2026, 4:05 PM EDT - 23 days ago

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Mar 9, 2026, 4:05 PM EDT - 5 weeks ago

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Feb 27, 2026, 4:15 PM EST - 6 weeks ago

Prothena Announces up to $100 Million Share Repurchase Plan

Feb 19, 2026, 4:05 PM EST - 7 weeks ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 12, 2026, 4:05 PM EST - 2 months ago

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Dec 12, 2025, 4:05 PM EST - 4 months ago

Prothena Announces Board of Directors Update

Nov 19, 2025, 4:05 PM EST - 5 months ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 11, 2025, 9:00 AM EST - 5 months ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 6, 2025, 4:05 PM EST - 5 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 30, 2025, 4:05 PM EDT - 5 months ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 1, 2025, 4:45 PM EDT - 6 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Aug 28, 2025, 4:05 PM EDT - 8 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 6, 2025, 9:00 AM EDT - 8 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 4, 2025, 4:05 PM EDT - 9 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 28, 2025, 4:05 PM EDT - 9 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jun 18, 2025, 4:05 PM EDT - 10 months ago

Prothena Announces Corporate Restructuring

Jun 16, 2025, 1:06 AM EDT - 10 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

May 27, 2025, 7:43 AM EDT - 11 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

May 23, 2025, 4:05 PM EDT - 11 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 9, 2025, 7:16 AM EDT - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

May 8, 2025, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Feb 20, 2025, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 17, 2025, 6:10 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 13, 2025, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

May 28, 2024, 4:05 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 8, 2024, 4:05 PM EDT - 2 years ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 4:05 PM EDT - 2 years ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Apr 15, 2024, 4:05 PM EDT - 2 years ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Mar 4, 2024, 4:05 PM EST - 2 years ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Feb 21, 2024, 4:05 PM EST - 2 years ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 8, 2024, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 10, 2023, 4:10 PM EDT - 3 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

buyandsold Apr. 11 at 2:58 PM

$PRTA just announced investment to "further elucidate the potential of our preclinical programs and CYTOPE® technology." Setting our dollars alight. I may exit in disgust.

0 · Reply

Doozio Apr. 8 at 5:20 AM

$PRTA chop chop huckleberries let’s go rockin up da Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

buyandsold Mar. 25 at 8:07 PM

$PRTA they better be in buyback Xtreme mode at this discounr or Im gonna lose it

0 · Reply

Quantumup Mar. 25 at 2:15 PM

0 · Reply

buyandsold Mar. 24 at 8:07 PM

$PRTA how this is not $12 i have no concept. Will they ever use the buyback. Restricted is a fantasy

0 · Reply

SuperGreenToday Mar. 24 at 1:52 AM

0 · Reply

buyandsold Mar. 23 at 1:50 PM

0 · Reply

takingstock73 Mar. 23 at 12:49 PM

$PRTA nice reiterate today

1 · Reply

SKVT Mar. 17 at 5:56 AM

$RHHBY roche will make a big announcement in AD/PD 2026. Prasinezumab trial 3 will be a game changer in parkinson's disease. $PRTA

2 · Reply

SKVT Mar. 17 at 5:54 AM

$PRTA ROCHE will make a big announcement in ADPD2026. Prasinezumab will be a big thing!!

0 · Reply

Itinerant Mar. 6 at 7:34 PM

$PRTA I am newly looking at this company. I do not understand why it has such a large market cap. It seems over valued to me. Perhaps it is just that it has two BP partners. However, there are other players in Parkinson's so that does not particularly impress me unless there is tech that I do not understand. Please give me some constructive input.

2 · Reply

buyandsold Mar. 4 at 10:02 PM

$PRTA actively holding. Does that make me watching part 3?

1 · Reply

takingstock73 Mar. 4 at 7:58 PM

$PRTA watching too

0 · Reply

MasterOfMyDomains Feb. 27 at 9:29 PM

$PRTA watching.....

1 · Reply

OfficialStocktwitsUser Feb. 21 at 11:05 AM

$PRTA RSI: 55.22, MACD: -0.1156 Vol: 0.40, MA20: 9.06, MA50: 9.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Feb. 20 at 6:45 PM

$PRTA earnings met… but is that enough? 👀 Q4 loss narrowed year over year, showing some progress, but revenues missed estimates. Now the real focus shifts to its outlined 2026 cash burn guidance and upcoming key milestones from partners — that’s where the next move could be decided. Is this a setup year or a turning point? Full breakdown here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-teaser-34515&ADID=SYND_STOCKTWITS_TWEET_2_2872993_TEASER_34515

0 · Reply

ZacksResearch Feb. 20 at 5:45 PM

$PRTA Q4 earnings reveal: Is the biotech’s slide over? 🤔 The company matched EPS expectations with a loss of 45 cents but missed revenue estimates, reporting $0.02M against the expected $3.0M. 📉 Full-year revenues for 2025 plunged 93% YoY, and shares have dropped 42% over the past year. Fundamental insights here 👉 https://www.zacks.com/stock/news/2872993/prothena-q4-earnings-meet-estimates-pipeline-progress-in-focus?cid=sm-stocktwits-2-2872993-body-34514&ADID=SYND_STOCKTWITS_TWEET_2_2872993_BODY_34514

0 · Reply

StocktwitsEarnings Feb. 19 at 9:13 PM

$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena anticipates full year 2026 net cash used in operating and investing activities of $50M, with an estimated $255M cash balance, largely due to a projected net loss of $67M.

0 · Reply

StocktwitsEarnings Feb. 19 at 9:13 PM

$PRTA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 62.96% YoY • Reported revenue of $0.02M down -99.01% YoY • Prothena expects full year 2026 net cash used in operating and investing activities to be $50 to $55M, ending the year with approximately $255M in cash (midpoint), not including up to $105M in clinical milestone payments.

0 · Reply

Estimize Feb. 19 at 4:00 PM

$PRTA reports after the close, Estimize Consensus -0.15 EPS and -0M Revs compared to WS http://www.estimize.com/prta/fq4-2025?utm_content=p

0 · Reply

TradeSurveyor Feb. 18 at 10:30 AM

$PRTA Rare disease biotech with regulatory catalysts.

0 · Reply

BillionerOfKing Feb. 17 at 10:45 PM

$PRTA Current Stock Price: $8.96 Contracts to trade: $9.0 PRTA Feb 20 2026 Call Entry: $0.36 Exit: $0.62 ROI: 73% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	565.25M
Revenue (ttm)	9.68M
Net Income (ttm)	-244.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	15.22
Profit Margin	-2,521.59%
Debt to Equity Ratio	0.00

Volume	334,000
Avg Vol	509,974
Day's Range	N/A - N/A
Shares Out	53.83M
Stochastic %K	72%
Beta	-0.33
Analysts	Sell
Price Target	$20.50